Stilla Technologies
Biotechnology company that focuses on accelerating the development of next-generation genetic tests .
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $225m | Acquisition | |
| Total Funding | 000k | ||
| EUR | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (45 %) | 72 % | 5 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (79 %) | (367 %) | (308 %) | (280 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
Source: Company filings or news article
Related Content
Stilla Technologies is a biotechnology startup that specializes in digital PCR (Polymerase Chain Reaction) workflows. The company's flagship product, Nio™+, is a powerful tool that simplifies the process of DNA quantification, a critical procedure in genetic research and diagnostics. The Nio™+ system supports 7 colors, has a capacity of 768 samples per 8-hour workday, and features continuous loading and user-friendly software.
Stilla Technologies serves a diverse range of clients, including research institutions, healthcare providers, and biotech companies. The company operates in the global biotechnology market, with a particular focus on genetic research and diagnostics.
The business model of Stilla Technologies revolves around the sale of its Nio™+ system and related products, such as its Crystal Digital PCR® Kits. These kits are used to detect and quantify specific genetic mutations in a single test, providing precise and reliable results.
Stilla Technologies has also developed applications for detecting ESR1 mutations in breast cancer samples and EGFR mutations in lung cancer samples. Additionally, the company offers a solution for on- and off-target detection in CRISPR-edited mammalian cell lines, a process that is typically laborious and time-consuming.
In summary, Stilla Technologies is a biotech startup that provides powerful and user-friendly solutions for DNA quantification, mutation detection, and genetic modification screening.
Keywords: Biotechnology, Digital PCR, DNA Quantification, Genetic Research, Diagnostics, ESR1 Mutation, EGFR Mutation, CRISPR, Genetic Modification, Mutation Detection.